{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:14:27Z","timestamp":1760238867272,"version":"build-2065373602"},"reference-count":58,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T00:00:00Z","timestamp":1599523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>In the last decade there has been tremendous effort in offering better therapeutic management strategies to patients with hematologic malignancies. These efforts have ranged from biological to clinical approaches and resulted in the rapid development of new approaches. The main \u201cproblem\u201d that comes with the high influx of newly approved drugs, which not only influences hematologists that frequently work with these drugs but also affects other healthcare professionals that work with hematologists in patient management, including intensive care unit (ICU) physicians, is they have to keep up within their specialty and, in addition, with the side-effects that can occur when encountering hematology-specific therapies. Nonetheless, there are few people that have an in-depth understanding of a specialty outside theirs. Thus, this manuscript offers an overview of the most common side-effects caused by therapies used in hematology nowadays, or that are currently being investigated in clinical trials, with the purpose to serve as an aid to other specialties. Nevertheless, because of the high amount of information on this subject, each chapter will offer an overview of the side-effects of a drug class with each reference of the section being intended as further reading.<\/jats:p>","DOI":"10.3390\/jcm9092903","type":"journal-article","created":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T09:03:48Z","timestamp":1599555828000},"page":"2903","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Overview of the Side-Effects of FDA- and\/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8292-911X","authenticated-orcid":false,"given":"Catalin","family":"Constantinescu","sequence":"first","affiliation":[{"name":"Intensive Care Unit, Ion Chiricuta Clinical Cancer Center, 400010 Cluj Napoca, Romania"},{"name":"Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, 400004 Cluj Napoca, Romania"},{"name":"Department of Anesthesia and Intensive Care, Iuliu Hatieganu University of Medicine and Pharmacy, 400000 Cluj Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergiu","family":"Pasca","sequence":"additional","affiliation":[{"name":"Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, 400004 Cluj Napoca, Romania"},{"name":"Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400000 Cluj Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3856-3784","authenticated-orcid":false,"given":"Alina-Andreea","family":"Zimta","sequence":"additional","affiliation":[{"name":"Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400000 Cluj Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiberiu","family":"Tat","sequence":"additional","affiliation":[{"name":"Intensive Care Unit, Ion Chiricuta Clinical Cancer Center, 400010 Cluj Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioana","family":"Rus","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ion Chiricuta Clinical Cancer Center, 400014 Cluj Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4129-8478","authenticated-orcid":false,"given":"Patric","family":"Teodorescu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, 400004 Cluj Napoca, Romania"},{"name":"Department of Hematology, Ion Chiricuta Clinical Cancer Center, 400014 Cluj Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina","family":"Iluta","sequence":"additional","affiliation":[{"name":"Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, 400004 Cluj Napoca, Romania"},{"name":"Department of Hematology, Ion Chiricuta Clinical Cancer Center, 400014 Cluj Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3075-499X","authenticated-orcid":false,"given":"Alina","family":"Tanase","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation, Fundeni Clinical Institute, 925200 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6031-8190","authenticated-orcid":false,"given":"Anca","family":"Colita","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation, Fundeni Clinical Institute, 925200 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4968-842X","authenticated-orcid":false,"given":"Olafur","family":"Sigurjonsson","sequence":"additional","affiliation":[{"name":"The Blood Bank, Landspitali\u2013the National University Hospital of Iceland, Snorrabraut 60, 101 Reykjavik, Iceland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5500-1519","authenticated-orcid":false,"given":"Ciprian","family":"Tomuleasa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, 400004 Cluj Napoca, Romania"},{"name":"Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400000 Cluj Napoca, Romania"},{"name":"Department of Hematology, Ion Chiricuta Clinical Cancer Center, 400014 Cluj Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1182\/blood-2015-09-659581","article-title":"Blood at 70: Its roots in the history of hematology and its birth","volume":"126","author":"Coller","year":"2015","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.seminhematol.2010.07.001","article-title":"Chronic Myeloid Leukemia: A Historical Perspective","volume":"47","author":"Goldman","year":"2010","journal-title":"Semin. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Jabbour, E., and Kantarjian, H. (2020). Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am. J. Hematol.","DOI":"10.1002\/ajh.25792"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3389\/fimmu.2017.01245","article-title":"Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?","volume":"8","author":"Marshall","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/qjmed\/hcu094","article-title":"Hypogammaglobulinaemia after rituximab treatment--incidence and outcomes","volume":"107","author":"Makatsori","year":"2014","journal-title":"QJM"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: Rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.3389\/fimmu.2018.02722","article-title":"CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma","volume":"9","author":"Morandi","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin\u2019s Lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5045\/br.2017.52.4.243","article-title":"Brentuximab vedotin: Clinical updates and practical guidance","volume":"52","author":"Yi","year":"2017","journal-title":"Blood Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.3495884","article-title":"Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation","volume":"236","author":"Reed","year":"1987","journal-title":"Science"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/0092-8674(87)90448-X","article-title":"Molecular analysis of mbcl-2: Structure and expression of the murine gene homologous to the human gene involved in follicular lymphoma","volume":"49","author":"Negrini","year":"1987","journal-title":"Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1073\/pnas.84.5.1329","article-title":"DNA rearrangements in human follicular lymphoma can involve the 5\u2019 or the 3\u2019 region of the bcl-2 gene","volume":"84","author":"Tsujimoto","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","first-page":"549","article-title":"Classification of lymphoma","volume":"102","author":"Taylor","year":"1978","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.212574","article-title":"Venetoclax: Evidence to date and clinical potential","volume":"8","author":"Desai","year":"2019","journal-title":"DIC"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/d41586-018-06751-0","article-title":"Cancer immunologists scoop medicine Nobel prize","volume":"562","author":"Ledford","year":"2018","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.semcancer.2019.06.012","article-title":"Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review","volume":"64","author":"Khan","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.leu.2404444","article-title":"Proteasome inhibitors: Antitumor effects and beyond","volume":"21","author":"Nencioni","year":"2007","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-2-36","article-title":"Mechanism of action of lenalidomide in hematological malignancies","volume":"2","author":"Kotla","year":"2009","journal-title":"J. Hematol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/2040620718775629","article-title":"Update on the role of lenalidomide in patients with multiple myeloma","volume":"9","author":"Holstein","year":"2018","journal-title":"Ther. Adv. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: Review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"ref_26","first-page":"7","article-title":"FLT3 Inhibitors: Recent advances and problems for clinical application","volume":"77","author":"Kiyoi","year":"2015","journal-title":"Nagoya J. Med. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1182\/blood-2019-127416","article-title":"Venetoclax in Combination with Gilteritinib in Patients with Relapsed\/Refractory Acute Myeloid Leukemia: A Phase 1b Study","volume":"134","author":"Perl","year":"2019","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/2040620714539906","article-title":"Bruton\u2019s tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: Focus on ibrutinib","volume":"5","author":"Aalipour","year":"2014","journal-title":"Ther. Adv. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/annonc\/mdx392","article-title":"Revival of PI3K inhibitors in non-Hodgkin\u2019s lymphoma","volume":"28","author":"Batlevi","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/jcp.25902","article-title":"Fibroblast dynamics as an in vitro screening platform for anti-fibrotic drugs in primary myelofibrosis","volume":"233","author":"Tomuleasa","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-019-0236-2","article-title":"Myelofibrosis in 2019: Moving beyond JAK2 inhibition","volume":"9","author":"Schieber","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Fuentes-Mattei, E., Bayraktar, R., Manshouri, T., Silva, A.M., Ivan, C., Gulei, D., Fabris, L., Soares do Amaral, N., Mur, P., and Perez, C. (2020). miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2. JCI Insight, 5.","DOI":"10.1172\/jci.insight.121781"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1080\/10428194.2018.1516881","article-title":"Mesenchymal stem cells in myeloproliferative disorders\u2014Focus on primary myelofibrosis","volume":"60","author":"Selicean","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3389\/fonc.2019.00872","article-title":"Persistent Basophilia May Suggest an \u201cAccelerated Phase\u201d in the Evolution of CALR-Positive Primary Myelofibrosis toward Acute Myeloid Leukemia","volume":"9","author":"Dobrowolski","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.3389\/fimmu.2019.02856","article-title":"Let\u2019s Talk about BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia","volume":"10","author":"Deak","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Constantinescu, C., Pasca, S., Tat, T., Teodorescu, P., Vlad, C., Iluta, S., Dima, D., Tomescu, D., Scarlatescu, E., and Tanase, A. (2020). Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?. J. Immunother. Cancer, 8.","DOI":"10.1136\/jitc-2020-000742"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Tat, T., Li, H., Constantinescu, C.-S., Onaciu, A., Chira, S., Osan, C., Pasca, S., Petrushev, B., Moisoiu, V., and Micu, W.-T. (2018). Genetically enhanced T lymphocytes and the intensive care unit. Oncotarget, 9.","DOI":"10.18632\/oncotarget.24637"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3389\/fimmu.2018.00239","article-title":"Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia","volume":"9","author":"Tomuleasa","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1389201019666180418095526","article-title":"CAR T-cell Therapy: A New Era in Cancer Immunotherapy","volume":"19","author":"Miliotou","year":"2018","journal-title":"CPB"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/1078155215618770","article-title":"A review of blinatumomab, a novel immunotherapy","volume":"22","author":"Newman","year":"2016","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/leu.2010.215","article-title":"Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"25","author":"Jabbour","year":"2011","journal-title":"Leukemia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/cc11304","article-title":"Clinical review: Serious adverse events associated with the use of rituximab\u2014A critical care perspective","volume":"16","author":"Kasi","year":"2012","journal-title":"Crit. Care"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/14740338.2016.1179277","article-title":"A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma","volume":"15","author":"Oak","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"225","DOI":"10.14740\/jocmr3750","article-title":"Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study","volume":"11","author":"Bajwa","year":"2019","journal-title":"J. Clin. Med. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"vii7","DOI":"10.1093\/rheumatology\/kez418","article-title":"Toxicities associated with checkpoint inhibitors\u2014An overview","volume":"58","author":"Spiers","year":"2019","journal-title":"Rheumatology"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Bascones-Martinez, A., Mattila, R., Gomez-Font, R., and Meurman, J.H. (2014). Immunomodulatory drugs: Oral and systemic adverse effects. Med. Oral., e24\u2013e31.","DOI":"10.4317\/medoral.19087"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2174\/1568009617666170214104426","article-title":"Immunomodulatory Drugs (IMiDs) in Multiple Myeloma","volume":"17","author":"Raza","year":"2017","journal-title":"CCDT"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Cho, S.-F., Lin, L., Xing, L., Li, Y., Yu, T., Anderson, K.C., and Tai, Y.-T. (2020). BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12061473"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e12910","DOI":"10.1111\/sji.12910","article-title":"Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed\/refractory multiple myeloma","volume":"92","author":"Feng","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: Mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"x21","DOI":"10.1093\/annonc\/mdz440","article-title":"Management of toxicity to isoform \u03b1-specific PI3K inhibitors","volume":"30","author":"Nunnery","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"Erratum: JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/2040620712461047","article-title":"Comprehensive review of JAK inhibitors in myeloproliferative neoplasms","volume":"4","author":"Sonbol","year":"2013","journal-title":"Ther. Adv. Hematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s40259-013-0040-7","article-title":"The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders","volume":"27","author":"Furumoto","year":"2013","journal-title":"BioDrugs"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/9\/2903\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:08:03Z","timestamp":1760177283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/9\/2903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,8]]},"references-count":58,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["jcm9092903"],"URL":"https:\/\/doi.org\/10.3390\/jcm9092903","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2020,9,8]]}}}